Q BioMed Has Licensing Agreement for Generic Bone Metastasis Pain Treatment

Q BioMed Has Licensing Agreement for Generic Bone Metastasis Pain Treatment
Q BioMed has closed an exclusive license and option agreement for Strontium Chloride (SR89), a radiopharmaceutical agent approved by the U.S. Food and Drug Administration for the treatment of pain associated with bone metastasis. The company said it will price the generic drug competitively, and patients will be able to buy it at a lower cost than

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *